Log in

Relevant bibliographies by topics / Deferoxamine and Deferasirox / Journal articles

To see the other types of publications on this topic, follow the link: Deferoxamine and Deferasirox.

Journal articles on the topic 'Deferoxamine and Deferasirox'

Author: Grafiati

Published: 3 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Deferoxamine and Deferasirox.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Deferasirox/deferoxamine." Reactions Weekly &NA;, no. 1357 (2011): 12. http://dx.doi.org/10.2165/00128415-201113570-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Delea, T. E., K. El Ouagari, and O. Sofrygin. "Cost of Current Iron Chelation Infusion Therapy and Cost-Effectiveness of Once-Daily Oral Deferasirox in Transfusion-Dependent Thalassemia Patients in Canada." Blood 108, no. 11 (2006): 3349. http://dx.doi.org/10.1182/blood.v108.11.3349.3349.

Full text

Abstract:

Abstract Background: Deferasirox (Exjade®) is a recently approved once-daily oral chelator that has been shown to produce reductions in liver iron concentrations and serum ferritin similar to those with infusional deferoxamine (Desferal®), in patients with β-thalassemia major or sickle cell disease (SCD) and chronic iron overload from blood transfusions. The objective of this study was to estimate the cost of deferoxamine administration in Canada and evaluate the cost-effectiveness of deferasirox versus deferoxamine for chronic iron overload from blood transfusions from the Ontario provincial

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Deferasirox/deferiprone/deferoxamine." Reactions Weekly &NA;, no. 1312 (2010): 21. http://dx.doi.org/10.2165/00128415-201013120-00073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Martin, Mike G., and Murat O. Arcasoy. "Deferasirox versus deferoxamine." Blood 108, no. 2 (2006): 774–76. http://dx.doi.org/10.1182/blood-2006-02-002436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

AHMED, A., M. KAMRAN, M. MUKHTAR, M. ALI та M. UMAIR. "COMPARISON OF DEFERASIROX AND DESFERRIOXAMINE AS IRON CHELATORS IN MULTI-TRANSFUSED PATIENTS OF Β-THALASSEMIA MAJOR". Biological and Clinical Sciences Research Journal 2023, № 1 (2023): 270. http://dx.doi.org/10.54112/bcsrj.v2023i1.270.

Full text

Abstract:

This study aimed to compare the efficacy of deferasirox and deferoxamine in improving hematological and immunological parameters in patients with transfusion-dependent β-thalassemia major. 200 patients were enrolled in the study, with 100 receiving deferasirox and 100 receiving deferoxamine. The study was conducted at Mayo Hospital, Lahore. The patients were followed up for six months, during which various hematological and immunological parameters were measured at regular intervals. The data were analyzed using appropriate statistical methods. Both deferasirox and deferoxamine effectively imp

APA, Harvard, Vancouver, ISO, and other styles

6

Pennell, Dudley J., John B. Porter, Antonio Piga та ін. "A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)". Blood 123, № 10 (2014): 1447–54. http://dx.doi.org/10.1182/blood-2013-04-497842.

Full text

Abstract:

Key Points In β-thalassemia major patients with severe iron burden, deferasirox was noninferior to deferoxamine for myocardial iron removal. The ejection fraction was stable during treatment for both deferasirox and deferoxamine.

APA, Harvard, Vancouver, ISO, and other styles

7

Batool, Narjis, Sadia Yasmeen, Rabia Anwar, and Zikria Saleem. "Evaluation of safety and efficacy of Deferoxamine compared with deferasirox in transfusion dependent beta thalassemia patients: a single center retrospective study." Hong Kong Journal of Paediatrics Research 4, no. 3 (2021): 42–47. http://dx.doi.org/10.37515/pediatric.5887.4303.

Full text

Abstract:

Purpose: The primary cause of mortality and morbidity in thalassemia major is iron overload. The objective of this study was to compare the safety and efficacy of deferoxamine and deferasirox in transfusion dependent beta thalassemia patients. Methods: A retrospective observational study was conducted among 178 patients. Patients were divided into two groups, deferoxamine group (90 patients) and deferasirox group (88 patients). Standardized data collection form was used to collect data. Clinical and demographic characteristics of patients were recorded by checking medical records. The collecte

APA, Harvard, Vancouver, ISO, and other styles

8

Mahmood, Abdul Kareem A., and Talib Almadany. "Combined Deferoxamine - Deferasirox in Treatment of Thalassemia Major with Iron Overload." Kufa Journal for Nursing Sciences 4, no. 1 (2014): 61–68. http://dx.doi.org/10.36321/kjns.vi20141.2447.

Full text

Abstract:

Objectives: to assess the efficacy and safety of combined Deferoxamine-defeosiraxregime and deferasiraox alone in group of thalassemia major patients Methodology: Forty two patients studied for one year, 29 patients of Deferoxamine (20mg/kg/day infusion, two days /week) and Deferasiraox. Efficacy of both regimes assessed by serum ferritin. safety assessed by liver enzyme, creatinine and blood urea. Results: Those patients who were on Deferasiraox alone showed significant them chosen for deferasiraox (40 mg/kg/day), 13 patients combined therapy reduction of serum ferritin (4482), to mean of ser

APA, Harvard, Vancouver, ISO, and other styles

9

Badeli, Hamidreza, Adel Baghersalimi, Sajjad Eslami, et al. "Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study." Oxidative Medicine and Cellular Longevity 2019 (April 21, 2019): 1–8. http://dx.doi.org/10.1155/2019/5461617.

Full text

Abstract:

Background. The life of patients with β-thalassemia major depends on blood transfusion. Regular blood transfusion leads to hemosiderosis in their main organs. The aim of this study was to compare the effects of deferasirox and deferoxamine on renal damage in patients with β-thalassemia major. Method. The present case-control study was conducted on 60 individuals who were referred to the 17th Shahrivar Tertiary Referral Hospital in Guilan province, Iran. In this study, patients with β-thalassemia major who used deferasirox (n=21) and patients who used deferoxamine (n=19) were evaluated. The con

APA, Harvard, Vancouver, ISO, and other styles

10

Ali, Rasul, Dler Ali, Zhyan Ahmed, Amal Ahmed, Dilvin Hassen, and Rozy Tahir. "Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia." Zanco Journal of Medical Sciences 24, no. 3 (2020): 354–59. http://dx.doi.org/10.15218/zjms.2020.042.

Full text

Abstract:

Background and objective: Patients on blood transfusion may develop complications related to iron overload and the effects of chelating agents (drugs), which adversely affect the liver in thalassemia, which is a genetic blood disorder of hemoglobin synthesis that causes severe anemia. This study aimed to assess the effect of deferasirox and deferoxamine drugs on liver enzyme activities (aspartate transaminase, alanine transaminase, and alkaline phosphatase), and serum ferritin level in β_thalassemic patients. Methods: This study was carried out in Erbil city from October 2017 to February 2018.

APA, Harvard, Vancouver, ISO, and other styles

11

Dhar, Tushit, Vaishali Tomar, and Subhash Dadeya. "Bilateral Nuclear Cataract with Deferasirox in a Patient of Beta-thalassemia: A Case Report and Literature Review." Delhi Journal of Ophthalmology 34, no. 2 (2024): 139–41. https://doi.org/10.4103/dljo.dljo_10_24.

Full text

Abstract:

We report the case of a 15-year-old child with beta-thalassemia developing bilateral cataracts while receiving deferasirox, a newer iron chelator. She had been taking deferasirox for the past 10 years while receiving monthly blood transfusions. A slit-lamp examination revealed a central cataract having nuclear morphology in both eyes. Lenticular opacities in beta-thalassemia patients typically do not involve the visual axis and are known to correlate positively with deferoxamine and deferiprone. With deferasirox increasingly superseding deferoxamine as an oral chelator, we delineate the morpho

APA, Harvard, Vancouver, ISO, and other styles

12

Grady, Robert W., Renzo Galanello, Dorothy A. Kleinert, Carole S. Paley, and Patricia J. Giardina. "Optimizing the Use of Deferasirox: Evidence of Synergy When Combined with Deferoxamine." Blood 116, no. 21 (2010): 5163. http://dx.doi.org/10.1182/blood.v116.21.5163.5163.

Full text

Abstract:

Abstract Abstract 5163 Introduction: Deferasirox (Exjade, ICL670) is an orally effective iron chelating agent approved for use in patients 2 years of age and older with transfusional iron overload. While it is effective as a single agent, there are patients who do not attain net negative iron balance despite being at the upper limit of approved dosing (40 mg/kg/day). Deferiprone (Ferriprox, L1) is another orally effective iron chelator. Through a series of metabolic iron balance studies we were able to demonstrate that various regimens involving the combined use of deferiprone and deferoxamine

APA, Harvard, Vancouver, ISO, and other styles

13

MUSTAFA, A., MT NADEEM, SA KHAN, J. ZAHID, A. ZAFAR, and M. WAHEED. "INCIDENCE OF DILATED CARDIOMYOPATHY IN PATIENTS OF THALASSEMIA MAJOR RECEIVING DEFERASIROX AND DEFEROXAMINE AS CHELATORS." Biological and Clinical Sciences Research Journal 2023, no. 1 (2023): 517. http://dx.doi.org/10.54112/bcsrj.v2023i1.517.

Full text

Abstract:

The objective of this study was to determine the frequency of dilated cardiomyopathy in patients with β-thalassemia major who received treatment with deferasirox and deferoxamine. A descriptive cross-sectional study was conducted in the Department of Paediatrics, Combined Military Hospital, Rawalpindi, from May 2022 to January 2023. All 746 paediatric patients aged between 4 to 18 years, of both genders, who had been diagnosed with β-thalassemia major and had received chelation with either deferasirox or deferoxamine for at least one continuous year were included. Patients who were non-complia

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Deferasirox dominates deferoxamine for iron control." Inpharma Weekly &NA;, no. 1643 (2008): 8. http://dx.doi.org/10.2165/00128413-200816430-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Choudhury, Nilufar Akhtar Banu, Md Abdul Wohab, Sazeda Sultana, and Md Belayet Hossain. "Comparison of Iron Chelators in the Management of Transfusion-Dependent Beta Thalassaemia Major Based on Serum Ferritin." International Journal of Current Research and Review 17, no. 01 (2025): 08–12. https://doi.org/10.31782/ijcrr.2024.17102.

Full text

Abstract:

Introduction: Iron overload remains a critical challenge in transfusion-dependent beta thalassemia major patients, necessitating effective chelation strategies. This study evaluated the comparative efficacy of combination therapy (deferoxamine plus deferasirox) versus deferasirox monotherapy in patients with severe iron overload. Methods: In this prospective, randomized controlled study, 50 transfusion-dependent beta thalassemia major patients with serum ferritin levels between 3,000-5,000 ng/mL were randomized into two groups. Group A (n=25) received combination therapy with subcutaneous defe

APA, Harvard, Vancouver, ISO, and other styles

16

Dr., Humble Bin Ahmed Dr. Samreen Manzoor Mehar Dr. Hafsa Rafi. "COMPARISON OF THALASSEMIA MAJOR ADOLESCENT CASES WHEN TREATED WITH DEFERASIROX AND DEFEROXAMINE IN TERMS OF MEAN LEVEL OF FERRITIN SERUM." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 07 (2018): 6627–32. https://doi.org/10.5281/zenodo.1318651.

Full text

Abstract:

<strong><em>Objective: </em></strong><em>Our research was aimed at the comparison of the level of </em><em>mean serum ferritin in the patients of major thalassemia after the treatment of deferoxamine and deferasirox.</em> <strong><em>Methods: </em></strong><em>Design of our research was randomized control which was carried out at Mayo Hospital, Lahore (Sept, 2016 to August, 2017) on 160 patients including both male and female with an age group of (1 – 14 years). All the patients were managed with blood transfusion in a year once and with a level of </em><em>serum ferritin (above 1000 mcg

APA, Harvard, Vancouver, ISO, and other styles

17

Chirnomas, Deborah, Amber Lynn Smith, Jennifer Braunstein, et al. "Deferasirox pharmacokinetics in patients with adequate versus inadequate response." Blood 114, no. 19 (2009): 4009–13. http://dx.doi.org/10.1182/blood-2009-05-222729.

Full text

Abstract:

AbstractTens of thousands of transfusion-dependent (eg, thalassemia) patients worldwide suffer from chronic iron overload and its potentially fatal complications. The oral iron chelator deferasirox has become commercially available in many countries since 2006. Although this alternative to parenteral deferoxamine has been a major advance for patients with transfusional hemosiderosis, a proportion of patients have suboptimal response to the maximum approved doses (30 mg/kg per day), and do not achieve negative iron balance. We performed a prospective study of oral deferasirox pharmacokinetics (

APA, Harvard, Vancouver, ISO, and other styles

18

Ezzat, Hatoon, R. Robert Schellenberg, Heather A. Leitch, and Linda M. Vickars. "Successful Tolerance of Deferasirox Following Desensitization for Significant Skin Rash." Blood 118, no. 21 (2011): 5280. http://dx.doi.org/10.1182/blood.v118.21.5280.5280.

Full text

Abstract:

Abstract Abstract 5280 BACKGROUND: Deferasirox is an oral iron chelator that has become available in recent years. The long term tolerability profile of deferasirox is still being evaluated, however a common side effect is skin rash, which may occur in up to 10% of patients. This is usually mild to moderate and resolves with continued treatment. More severe rash may require interruption of therapy and reintroduction of deferasirox at a lower dose followed by gradual dose escalation. A short course of corticosteroids may be used. Occasional cases of angioedema have been reported for which cessa

APA, Harvard, Vancouver, ISO, and other styles

19

Mosawi, Ahmed Mohammed Taqi Al, and Haitham Mahmood Kadhim. "Comparison of Deferasirox (Exjade\(^®\)) and Deferoxamine (Desferal\(^®\)) Effects on Iron Overload in Patients with Blood Transfusion-Dependent \(\beta\)-Thalassemia Major in Iraq." Azerbaijan Pharmaceutical and Pharmacotherapy J 22, no. 2 (2023): 160–63. http://dx.doi.org/10.61336/appj/22-2-34.

Full text

Abstract:

Objectives: The aim of the study was to compare between the effects of two most common iron chelating agents (Deferasirox and Deferoxamine) used in the management of beta-thalassemia major. Materials and Methods: A Cross section study conducted in Thalassemia and hereditary blood Diseases Center of Kut hospitals in September 2022, all the included patients were of \(\beta\)-thalassemia major type those treated with blood transfusion and iron chelating agents. Patients were divided into two groups. First group included 20 patients receiving Deferasirox (Exjade) Novartis Europharm Basil, Switzer

APA, Harvard, Vancouver, ISO, and other styles

20

Jordan, Lanetta B., Francis Vekeman, Anirban Sengupta, Mitra Corral, Amy Guo, and Mei Sheng Duh. "Persistence and Compliance of Deferoxamine Versus Deferasirox in Medicaid Patients with Sickle-Cell Disease." Blood 114, no. 22 (2009): 1982. http://dx.doi.org/10.1182/blood.v114.22.1982.1982.

Full text

Abstract:

Abstract Abstract 1982 Poster Board I-1004 Background: Patients with sickle-cell disease (SCD) receiving chronic transfusions of red blood cells are at risk of developing serious adverse effects. Iron chelating therapies (ICTs) help eliminate iron surplus by binding with plasma iron to form a non-toxic conjugate that can be safely excreted from the body. Two iron chelating agents are currently available in the US: deferoxamine (DFO) is an injectable formulation and deferasirox (Exjade®) is an oral suspension. This study compared the frequency of hospitalizations, persistence, and compliance of

APA, Harvard, Vancouver, ISO, and other styles

21

Jasim, Talib Abduljaleel. "Iron Chelator in Patients with Sickle Cell Anemia, Comparative Study." Kufa Journal for Nursing Sciences 4, no. 3 (2015): 103–10. http://dx.doi.org/10.36321/kjns.vi20143.2769.

Full text

Abstract:

Background: the two main reasons for blood transfusion in sickle cell disease are to correct anemia so that the oxygen-carrying capacity of the blood is improved, and to treat or prevent painful vasoocclusive by lowering the proportion of sickle cell hemoglobin. Iron over load will be evitable. Objectives: The aim of this study is to asses safety and efficiency of different chelation therapy. Methodology: Fifty two patients divided in to two equal group, for treatment by combined Deferoxamine-Deferasirox therapy and on Deferasirox alone. Results: both drug regimens proved to have no adverse ef

APA, Harvard, Vancouver, ISO, and other styles

22

Neufeld, Ellis J. "Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions." Blood 107, no. 9 (2006): 3436–41. http://dx.doi.org/10.1182/blood-2006-02-002394.

Full text

Abstract:

For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Strategies to reduce cardiac disease by improving chelation regimens have been of the highest priority. These strategies have included development of novel oral iron chelators to improve compliance, improved

APA, Harvard, Vancouver, ISO, and other styles

23

Mohammed Ali, Younis Hassan, Hashim Abdulsattar Jabbar, and Entedhar Rifaat Sarhat. "Early Detection Of Glomerular Dysfunction In Beta Thalassemia Major Patients Undergoing Chelation Therapy." International Journal of Environmental Sciences 11, no. 12s (2025): 476–83. https://doi.org/10.64252/mnj5ke76.

Full text

Abstract:

Background: Thalassemia is one of the prevalent hemoglobinopathies caused by gene mutation leading to chronic anemia. Iron overload and direct nephrotoxic effects of chelators are the largely accepted explanations for the mechanisms of renal glomerular impairment in BTM. The aim of this study was to early detection of glomerular dysfunction in BTM patients receiving iron chelators using novel biomarker. Methods: The study included 60 patients with BTM receiving iron chelators: group 1 receiving Deferoxamine (DFO) and group 2 receiving Deferasirox (DFX). Control group include 30 healthy people

APA, Harvard, Vancouver, ISO, and other styles

24

Barzegari, Saeed, Hosein Rostamian, Ehsan Firoozi-Majd, and Ibrahim Arpaci. "Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia." Pharmacy 13, no. 3 (2025): 86. https://doi.org/10.3390/pharmacy13030086.

Full text

Abstract:

Iron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications. Selecting the most appropriate chelation therapy from the available options is a complex decision for healthcare professionals. To support this decision-making process, this study investigates the application of the “Fuzzy Analytic Hierarchy Process” (FAHP) for medication selection in thalassemia patients requiring iron-chelation therapy. In this study, 20 hematologists participated, and matrices related to the FAHP model were us

APA, Harvard, Vancouver, ISO, and other styles

25

Jeong, Dae-Chul, Nack-Gyun Chung, Bin Cho, Sung-Yong Kim, Chi Wha Han, and Hack Ki Kim. "Deferasirox Might Induce Immunosuppression Comparable to Deferoxamine." Blood 110, no. 11 (2007): 3755. http://dx.doi.org/10.1182/blood.v110.11.3755.3755.

Full text

Abstract:

Abstract Background: The iron chelating agents (ICA) have various biological effects besides iron chelation, including induction of apoptosis and immune modulation. Deferoxamine (DFO) is known to have some immunosuppressive effects. Deferasirox (DFS) is a new oral iron chelating agent, and its biologic effects are not known clearly. We investigated the immunosuppressive effects of DFS in comparison with DFO. Materials and Methods: We obtained spleen cells (SP) from 5 week-old female C57BL/6 (B6, H-2b) and BLAB/c (H-2d). The cytotoxicity of ICA at various concentrations was examined by CCK8 met

APA, Harvard, Vancouver, ISO, and other styles

26

Seema Aftab, Amber Kamran, and Shahina Hanif. "Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine." ANNALS OF ABBASI SHAHEED HOSPITAL AND KARACHI MEDICAL & DENTAL COLLEGE 22, no. 4 (2017): 243–48. http://dx.doi.org/10.58397/ashkmdc.v22i4.139.

Full text

Abstract:

Objective: To compare the mean serum ferritin levels in thalassaemia major patients after giving deferasirox and deferoxamine. This is a randomised control trial conducted at the Department of Paediatrics, Civil Hospital, Karachi from 29th January 2014 to 28th July 2014. Methods: A total of 160 patients of either gender, with age between 1 to 14 years, who received blood transfusion at least once a month for one year and had serum ferritin >1000 mcg/L were included. Each enrolled patient was randomly allocated to group-A (deferoxamine) or group-B (deferasirox). Pre- and post-treatment

APA, Harvard, Vancouver, ISO, and other styles

27

Cohen, Alan R., Ekkehard Glimm та John B. Porter. "Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major". Blood 111, № 2 (2008): 583–87. http://dx.doi.org/10.1182/blood-2007-08-109306.

Full text

Abstract:

The success of chelation therapy in controlling iron overload in patients with thalassemia major is highly variable and may partly depend on the rate of transfusional iron loading. Using data from the 1-year phase III study of deferasirox, including volumes of transfused red blood cells and changes in liver iron concentration (LIC) in 541 patients, the effect of iron loading on achieving neutral or negative iron balance was assessed in patients receiving different doses of deferasirox and the comparator deferoxamine. After dose adjustment, reductions in LIC after 1 year of deferasirox or defer

APA, Harvard, Vancouver, ISO, and other styles

28

Fischer, Roland, Regine Grosse, Rainer Engelhardt, Peter Nielsen, Oliver Leismann, and Gritta E. Janka. "Intraindividual Comparison between Deferasirox and Deferoxamine in Thalassemia." Blood 110, no. 11 (2007): 2776. http://dx.doi.org/10.1182/blood.v110.11.2776.2776.

Full text

Abstract:

Abstract In patients with iron overload from chronic blood (RBC) transfusion a new era of chelation treatment has been started with the availability of 3 chelators, their combinations, and other potential modifiers of tissue iron distribution. The decision about the chelator type and its dose would be facilitated if a mean chelation response could be forecasted. With the knowledge of a chelator’s molar efficacy, one could calculate the dose necessary to compete with the iron influx from blood transfusions. An open compartment model as developed for deferoxamine (DFO) and deferiprone (DFP) (Bri

APA, Harvard, Vancouver, ISO, and other styles

29

Hider, Robert, Xiaole Kong, Tim Luker, Kelly Conlon, and Rachel Harland. "SPD602 Is a Selective Iron Chelator Which Is Able To Mobilise The Non-Transferrin-Bound Iron Pool." Blood 122, no. 21 (2013): 1673. http://dx.doi.org/10.1182/blood.v122.21.1673.1673.

Full text

Abstract:

Abstract Currently there are three iron chelators in clinical use, deferoxamine, deferiprone and deferasirox. Each has its limitations and although both deferiprone and deferasirox have the advantage over deferoxamine of being orally active, both are associated with a range of side effects (Neufeld, Blood 2006;107:3436). SPD602 (formerly known as FBS0701) is a tridentate, orally administered iron chelator in clinical development that has shown evidence of effect in a phase 2 clinical trial (Neufeld et al. Blood 2012;119:3263). Here, we present a comparison of clinically relevant physicochemica

APA, Harvard, Vancouver, ISO, and other styles

30

Pilo, Federica, Anna Angela Di Tucci, Laura Dessì, and Emanuele Angelucci. "Management of Transfusional Chronic Iron Overload: Focus on Deferasirox." Clinical Medicine. Therapeutics 1 (January 2009): CMT.S1970. http://dx.doi.org/10.4137/cmt.s1970.

Full text

Abstract:

Most patients with hereditary or chronic acquired anemias are dependent on regular red cell transfusions. Untreated iron overload from transfusions is responsible for morbidity and mortality in patients with thalassemia major. However, clinical consequences of parenchymal iron overload have been reported not only in thalassemia major but also in patients with myelodysplastic syndrome. The current standard in iron chelation therapy is deferoxamine mesylate (Desferal®). Deferasirox is the first oral iron chelator approved in the Europe Union for use in patients with transfusional iron overload w

APA, Harvard, Vancouver, ISO, and other styles

31

Jung, Yeong Suk, E. Young Bae, Nack Gyun Chung, et al. "Comparison of Immune Responses Induced by Deferoxamine and Deferasirox." Korean Journal of Hematology 43, no. 3 (2008): 150. http://dx.doi.org/10.5045/kjh.2008.43.3.150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Lal, Ashutosh, John Porter, Nancy Sweeters, et al. "Combined chelation therapy with deferasirox and deferoxamine in thalassemia." Blood Cells, Molecules, and Diseases 50, no. 2 (2013): 99–104. http://dx.doi.org/10.1016/j.bcmd.2012.10.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Trachtenberg, Felicia, Elliott Vichinsky, Dru Haines, et al. "Iron chelation adherence to deferoxamine and deferasirox in thalassemia." American Journal of Hematology 86, no. 5 (2011): 433–36. http://dx.doi.org/10.1002/ajh.21993.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

M. Mahmoud, Samir, та Samir M. Mahmoud. "Evaluation of Certain Inflammatory Markers in Transfusion Dependent β-Thalassemic Patients". Tikrit Journal of Pharmaceutical Sciences 9, № 1 (2023): 80–90. http://dx.doi.org/10.25130/tjphs.2013.9.1.8.80.90.

Full text

Abstract:

To determine the serum concentration of certain inflammatory markers including TNF-α and hs-CRPβ-thalassemic patients on different types of treatmentand to investigate the possible correlation between these inflammatory markers and iron overload referred to by serum ferritin concentration, moreoverto assesswhether inflammation in β-thalassemia could be controlled by deferasirox or deferoxamine as compared to transfusion dependent patients without iron chelator. Ninety transfusion dependent β-thalassemic children with age range 13–75 months were included in this study, and 30 age and sex matche

APA, Harvard, Vancouver, ISO, and other styles

35

Cappellini, M. Domenica, Mohamed Bejaoui, Leyla Agaoglu, et al. "Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up." Blood 118, no. 4 (2011): 884–93. http://dx.doi.org/10.1182/blood-2010-11-316646.

Full text

Abstract:

Abstract Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year, phase 3, randomized trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ≥ 1 deferasirox dose, 66.8% completed the study; 43 patients (7.7%) discontinued

APA, Harvard, Vancouver, ISO, and other styles

36

Forni, Gian Luca, Marina Podestà, Marco Musso та ін. "Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with β-Thalassemia Major". Blood 120, № 21 (2012): 5178. http://dx.doi.org/10.1182/blood.v120.21.5178.5178.

Full text

Abstract:

Abstract Abstract 5178 Several reports established an association between iron chelation therapy with deferasirox and hematopoietic improvement in patients with myelodysplastic syndromes. Data in β-thalassemia major (TM) patients is absent. We evaluated levels (frequency and aboslute number) of several hematopoietic peripheral progenitors (HPP: Colony Forming Unit-Granulocyte/Macrophage [CFU-GM], Erythroid Burst-Forming Unit [BFU-E], Colony Forming Unit-Granulocyte, Erythrocyte, Macrophage, Megakaryocyte [CFU-GEMM], and Long Term Culture-Initiating Cells [LTC-IC]) in 26 TM patients (median age

APA, Harvard, Vancouver, ISO, and other styles

37

Wu, Dijiong, Xiaowen Wen, Wenbin Liu, Huijin Hu, Baodong Ye, and Yuhong Zhou. "Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload." Drug Design, Development and Therapy Volume 12 (May 2018): 1081–91. http://dx.doi.org/10.2147/dddt.s161086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Cappellini, Maria Domenica, Antonis Kattamis, Christos Kattamis, et al. "Switching from Deferoxamine (Desferal®, DFO) to Deferasirox (Exjade®) Maintains Effective Control of Iron Levels in Patients with Thalassemia Major (TM)." Blood 112, no. 11 (2008): 5416. http://dx.doi.org/10.1182/blood.v112.11.5416.5416.

Full text

Abstract:

Abstract Background: The clinical outcome of transfusion-dependent TM patients with iron overload has been shown to depend on the dose and frequency of deferoxamine (DFO) use. However, the demanding regimen of slow subcutaneous infusions often leads to poor compliance. Deferasirox (Exjade®), a once-daily oral chelator, has potential compliance advantages. Doses of 20–30 mg/kg/day are non-inferior to DFO &gt;35 mg/kg in TM patients with baseline liver iron concentration (LIC) &gt;7 mg Fe/g dry weight (dw). This analysis reports efficacy and safety data from TM patients with iron overloa

APA, Harvard, Vancouver, ISO, and other styles

39

Origa, Raffaella. "Combination Therapies in Iron Chelation." Thalassemia Reports 4, no. 3 (2014): 4862. http://dx.doi.org/10.4081/thal.2014.4862.

Full text

Abstract:

The availability of oral iron chelators and new non-invasive methods for early detection and treatment of iron overload, have significantly improved the life expectancy and quality of life of patients with β thalassemia major. However, monotherapy is not effective in all patients for a variety of reasons. We analyzed the most relevant reports recently published on alternating or combined chelation therapies in thalassemia major with special attention to safety aspects and to their effects in terms of reduction of iron overload in different organs, improvement of complications, and survival. Wh

APA, Harvard, Vancouver, ISO, and other styles

40

Grosse, Regine, Gisela Janssen, Rainer Engelhardt, et al. "Chelator Efficacy of Deferasirox and Deferoxamine Determined by SQUID Biosusceptometry." Blood 108, no. 11 (2006): 1779. http://dx.doi.org/10.1182/blood.v108.11.1779.1779.

Full text

Abstract:

Abstract Chelation treatment of patients with iron overload from chronic blood (RBC) transfusion needs continuous monitoring of iron stores, iron influx rates from RBC, chelation dose rates, and compliance. Molar chelator efficacy depicts the combined effect from these variables. Treatment should always aim to maximize the efficacy of a certain chelator in an individual patient in order to reduce organ damage from iron toxicity. In a prospective trial on the oral chelator deferasirox, a total of 12 patients with b-thalassemia major have been followed by SQUID biomagnetic liver susceptometry in

APA, Harvard, Vancouver, ISO, and other styles

41

Goulas, Vasilis, Alexandra Kourakli-Symeonidis, and Charalambos Camoutsis. "Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia." ISRN Hematology 2012 (December 17, 2012): 1–8. http://dx.doi.org/10.5402/2012/139862.

Full text

Abstract:

This prospective study assessed the quality of life of patients with homozygous transfusion-dependent beta-thalassemia in Greece receiving three different iron chelation treatments. Patients enrolled were receiving one of the following chelation therapies: deferoxamine (n=21), deferasirox (n=75), or deferoxamine in combination with deferiprone (n=39). The three groups were compared in terms of their quality of life, satisfaction and adherence to treatment, control of their health, and self-esteem through the completion of five questionnaires. A higher percentage of patients receiving deferoxam

APA, Harvard, Vancouver, ISO, and other styles

42

Pennell, Dudley J., John B. Porter, Antonio Piga та ін. "A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA)." Blood 120, № 21 (2012): 2124. http://dx.doi.org/10.1182/blood.v120.21.2124.2124.

Full text

Abstract:

Abstract Abstract 2124 Background: Without effective iron chelation therapy (ICT), patients with transfusional iron overload are at risk of excess iron-related cardiac complications. Cardiac iron accumulation can be measured using T2* magnetic resonance (normal >20 ms, high risk <10 ms). There are few randomized controlled trials assessing ICT for cardiac iron removal. CORDELIA is a Phase II, multinational, randomized comparison of efficacy and safety of 1-yr treatment with deferasirox or deferoxamine (DFO). Primary objective was non-inferiority of deferasirox vs DFO for cardiac iron rem

APA, Harvard, Vancouver, ISO, and other styles

43

Vichinsky, Elliott. "Iron Overload and Iron Chelation Therapy in Pediatric Patients." Oncology & Hematology Review (US) 02 (2009): 64. http://dx.doi.org/10.17925/ohr.2009.02.0.64.

Full text

Abstract:

Iron overload is an unfortunate clinical consequence of repeated blood transfusions that can cause significant organ damage, morbidity, and mortality in the absence of proper treatment. Pediatric patients with transfusion-dependent pathologies face the additional risk of growth failure and poor sexual development owing to iron build-up in the anterior pituitary gland. Iron chelation therapy is necessary for the removal of excess iron, but treatment efficacy and success are highly dependent on patient compliance. Deferoxamine is a well-established but inconvenient therapy requiring parenteral a

APA, Harvard, Vancouver, ISO, and other styles

44

Glickstein, Hava, Rinat Ben El, Gabi Link, et al. "Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences." Blood 108, no. 9 (2006): 3195–203. http://dx.doi.org/10.1182/blood-2006-05-020867.

Full text

Abstract:

Abstract Labile iron in hemosiderotic plasma and tissue are sources of iron toxicity. We compared the iron chelators deferoxamine, deferiprone, and deferasirox as scavengers of labile iron in plasma and cardiomyocytes at therapeutic concentrations. This comprised chelation of labile plasma iron (LPI) in samples from thalassemia patients; extraction of total cellular iron; accessing labile iron accumulated in organelles and preventing formation of reactive-oxidant species; and restoring impaired cardiac contractility. Neonatal rat cardiomyocytes were used for monitoring chelator extraction of L

APA, Harvard, Vancouver, ISO, and other styles

45

Alam, Muhammad Mahbub Ul, M. Alauddin, M. Jollilur Rahman, Rawshan Akhter, and Chinmoy Kanti Das. "Comparative Effects of Iron Chelators on the Transfusion-Dependent Beta-Thalassemia Patients." TAJ: Journal of Teachers Association 26 (November 28, 2018): 14–19. http://dx.doi.org/10.3329/taj.v26i0.37579.

Full text

Abstract:

This prospective study assessed the quality of life of patients with transfusion-dependent beta-thalassemia receiving three different iron chelation treatments. Patients enrolled were receiving one of the following chelation therapies: Group-I: deferoxamine (n=21), Group-II: deferasirox (n=75) and Group-III: deferoxamine in combination with deferiprone (n=39). The three groups were compared in terms of their quality of life, satisfaction and adherence to treatment, control of their health, and self-esteem through the completion of five questionnaires. A higher percentage of patients receiving

APA, Harvard, Vancouver, ISO, and other styles

46

Porter, John, Donald K. Bowden, Marina Economou та ін. "Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence inβ-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial". Anemia 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/297641.

Full text

Abstract:

Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data fromβ-thalassemia (n=274) and myelodysplastic syndrome (MDS) patients (n=168) patients participating in the Evaluation of Patients' Iron Chelation with Exjade (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb study investigating the efficacy and safety of the once-daily oral iron chelator, deferasirox. HRQOL and

APA, Harvard, Vancouver, ISO, and other styles

47

Glickstein, Hava, Hanspeter Nick, and Zvi I. Cabantchik. "Susceptibility of Endocrine, Cardiac, and Macrophage Cell Lines to Iron-Mediated Oxidative Damage and the Cytoprotective Effect of the Orally Active Chelator Deferasirox (Exjade®, ICL670)." Blood 110, no. 11 (2007): 3825. http://dx.doi.org/10.1182/blood.v110.11.3825.3825.

Full text

Abstract:

Abstract Systemic iron overload (primary or secondary) affects hepatic and extrahepatic functions by damaging endocrine and cardiac tissue. In vitro studies with pancreatic Min6 and pituitary Att20 cells and with cardiac H9c2 cells (all highly active in endocytotic activity) indicated that their exposure to labile iron, acutely or chronically, lead to major intracellular iron accumulation in organelles (endosomes, mitochondria, cytosol) and increased reactive oxygen species (ROS) formation when redox challenged. Among the functions affected by metal-evoked ROS are permselectivity (calcein leak

APA, Harvard, Vancouver, ISO, and other styles

48

Walter, Patrick, Eric Macklin, John Porter та ін. "Control of Oxidant-Stress and Inflammation by Iron Chelators Deferasirox (ICL670) or Deferoxamine in β-Thalassemia: An Ancillary Study of the Novartis CICL670A0107 Trial." Blood 106, № 11 (2005): 3598. http://dx.doi.org/10.1182/blood.v106.11.3598.3598.

Full text

Abstract:

Abstract Objective: We examined whether oxidant-stress and inflammation in β-thalassemia can be controlled by deferasirox as effectively as by deferoxamine (DFO) through analysis of body iron burden and biomarkers of lipid peroxidation and inflammation. Methods: Thalassemia Clinical Research Network patients participating in the Novartis CICL670A0107 trial (a randomized comparison of deferasirox, an oral iron chelator, vs. DFO) were eligible and 44 (25 male, 21.8±11.1 yrs) were enrolled in the study. Blood samples were obtained fasting after a 5-day washout of DFO prior to commencing treatment

APA, Harvard, Vancouver, ISO, and other styles

49

Kim, Jin Hyun, and Youn Hee Kim. "Economic Evaluation of Iron Chelation Agents: Oral Deferasirox versus Infusional Deferoxamine." Korean Journal of Hematology 43, no. 2 (2008): 89. http://dx.doi.org/10.5045/kjh.2008.43.2.89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lal, Ashutosh, Nancy Sweeters, Vivian Ng, et al. "Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia." Blood 116, no. 21 (2010): 4269. http://dx.doi.org/10.1182/blood.v116.21.4269.4269.

Full text

Abstract:

Abstract Abstract 4269 Therapeutic regimens that combine two iron chelators may enhance chelation efficiency by improving access to different tissue iron stores and control of the toxic labile iron pool. The combination of two chelators can reduce toxicity through averting the need for high doses of a single drug, but it is essential to establish the safety such regimens. We therefore explored the combined use of deferasirox (DSX) and deferoxamine (DFO) in patients with transfusion-dependent thalassemia who had failed standard chelation therapy with single drug. Patients were eligible if the l

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!